Gunderson Dettmer represented client BillionToOne, a next-generation molecular diagnostics company, in the announcement of its $125 million Series C financing co-led by Adams Street Partners and Hummingbird Ventures. BillionToOne focuses on the development of molecular counting technology that increases the resolution of disease detection using cell-free DNA. The new capital will enable the company to expand its commercial and clinical teams, scale-up lab capacity, and conduct clinical studies for their liquid biopsy test.

In the announcement of the transaction, Co-Founder and CEO of BillionToOne Atay Oghuzan Ph.D. said, “Our prenatal test is solving a critical unmet medical need. We continue to grow at an incredible rate, and we are building out an ever-increasing set of larger laboratory facilities. The current funding will be used to support our prenatal test growth while launching our differentiated liquid biopsy test that will transform oncology care.”

The Gunderson deal team was led by corporate partner Nick Harley and included corporate associates Alex Whatley and Vincent Dutkowski, and of counsel Ryan Enchelmayer. 

Companies:
BillionToOne
Adam Street Partners
Hummingbird Ventures